GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Price-to-Tangible-Book

NurExone Biologic (TSXV:NRX) Price-to-Tangible-Book : 12.32 (As of Apr. 17, 2025)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Price-to-Tangible-Book?

As of today (2025-04-17), NurExone Biologic's share price is C$0.69. NurExone Biologic's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was C$0.06. Hence, NurExone Biologic's Price to Tangible Book Ratio of today is 12.32.

The historical rank and industry rank for NurExone Biologic's Price-to-Tangible-Book or its related term are showing as below:

TSXV:NRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.82   Med: 10.27   Max: 59
Current: 11.5

During the past 3 years, NurExone Biologic's highest Price to Tangible Book Ratio was 59.00. The lowest was 4.82. And the median was 10.27.

TSXV:NRX's Price-to-Tangible-Book is ranked worse than
89.38% of 1205 companies
in the Biotechnology industry
Industry Median: 2.41 vs TSXV:NRX: 11.50

A closely related ratio is called PB Ratio. As of today, NurExone Biologic's share price is C$0.69. NurExone Biologic's Book Value per Sharefor the quarter that ended in Sep. 2024 was C$0.06. Hence, NurExone Biologic's P/B Ratio of today is 12.32.


NurExone Biologic Price-to-Tangible-Book Historical Data

The historical data trend for NurExone Biologic's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Price-to-Tangible-Book Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Tangible-Book
- 5.91 59.00

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.50 59.00 10.27 12.45 10.18

Competitive Comparison of NurExone Biologic's Price-to-Tangible-Book

For the Biotechnology subindustry, NurExone Biologic's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Price-to-Tangible-Book falls into.


;
;

NurExone Biologic Price-to-Tangible-Book Calculation

NurExone Biologic's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=0.69/0.056
=12.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


NurExone Biologic Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines